Table 1.
Characteristic and treatment characteristic of the included studies.
| Study(phase, country) | Regimens | Patients(N) | Male (N) | Median age(Y) | mPFS (M) | mOS (M) | ORR (%) | ≥3grade Neutropenia (N) | Dosage |
|---|---|---|---|---|---|---|---|---|---|
| Sharma et al., (9) | FUFA | 28 | 5 | 47 | 3.5 | 4.6 | 14.3 | 2 | FUFA: 5-FU: 425mg/m²+LV 20mg/m² intravenous (IV) bolus weekly for 30 weeks |
| (India III) | Gemox | 27 | 5 | 49 | 8.5 | 9.5 | 30.7 | 10 | GEMOX: Gemcitabine: 900mg/m²+Oxaliplatin: 80 mg/m² |
| BSC | 27 | 6 | 51 | 2.8 | 4.5 | 0 | |||
| Kim et al., (5) | Gemox | 114 | 70 | 64 | 5.3 | 10.4 | 24.6 | 16 | GEMOX: Gemcitabine: 1000mg/m²/d1, d8+Oxaliplatin: 100 mg/m²/d1。 |
| (Korea III) | Xelox | 108 | 74 | 62 | 5.8 | 10.6 | 15.7 | 5 | XELOX: Capecitabine: 1000mg/m²/d1-14 bid po+Oxaliplatin: 130mg/m²/d1 |
| Valle et al., (10) | GP+cediranib | 62 | 34 | 68 | 8 | 14.1 | 44 | 26 | Cisplatin: 25 mg/m²+Gemcitabine: 1000 mg/m² d1, 8 |
| (UK II) | GP | 62 | 28 | 65 | 7.4 | 11.9 | 19 | 23 | Cediranib: 20mg qd po |
| Valle et al., (3) | GP | 204 | 96 | 64 | 8 | 11.7 | 26.1 | 50 | GP: Cisplatin: 25mg/m2+Gemcitabine: 1000mg/m², d1, 8 |
| (UK III) | GEM | 206 | 98 | 63 | 5 | 8.1 | 15.5 | 33 | GEM: Gemcitabine: 1000mg/m², d1, 8, 15 |
| Dos Santos et al., (11) | IP | 24 | 5.3 | 11.9 | 35 | IP: CPT-11: 65mg/m² d1, 8+Cisplatin 60mg/m² d1 | |||
| (Brazil II) | GP | 23 | 7.8 | 9.8 | 31.8 | GP: Gemcitabine: 1000mg/m² d1, 8+Cisplatin 25mg/m² d1 | |||
| Huang et al., (8) | GS | 32 | 19 | 5.6 | 8.2 | 18.8 | 21 | GS: Gemcitabine: 1000 mg/m² d1, 15+S1: 80‐120mg/m², bid po d1-14 | |
| (China) | GP | 34 | 22 | 6.5 | 10.2 | 20.6 | 20 | GP: Gemcitabine: 1000 mg/m² d1, 8+Cisplatin 25mg/m², d1, 8 q3w | |
| Morizane et al., (4) | GP | 175 | 99 | 67 | 5.8 | 13.4 | 32.4 | 104 | GS: Gemcitabine: 1000 mg/m², d1, 8+S1:80‐100mg/m², bid po d1-14 |
| (Japan III) | GS | 179 | 97 | 67 | 6.8 | 15.1 | 29.8 | 106 | GP: Gemcitabine: 1000 mg/m², d1, 8+Cisplatin: 25mg/m², d1, 8 |
| Li et al., (12) | GS | 25 | 19 | 57 | 4.9 | 11 | 36 | Gemcitabine: 1000 mg/m², d1, 8, 15 | |
| (China) | GEM | 25 | 16 | 55 | 3.7 | 10 | 24 | S1: 80‐100mg/m², bid po d1-14 | |
| S1 | 25 | 19 | 57 | 1.6 | 6 | 8 | |||
| Schinzari et al., (6) | FUFA | 23 | 10 | 61 | 2.8 | 7.5 | 21.7 | 1 | LV: 100 mg/m² d1, 2, q2w |
| (Italy II) | Folfox 4 | 25 | 11 | 62 | 5.2 | 13 | 28 | 2 | 5-FU: 400 mg/m² d1, 2+5-FU: 1200 mg/m² (46 hours infusion) |
| BSC | 25 | 13 | 65 | 0 | Oxaliplatin: 85 mg/m² d1, q2w | ||||
| Okusaka et al., (13) | GP | 41 | 18 | 65 | 5.8 | 11.2 | 19.5 | 17 | GEM: Gemcitabine: 1000mg/m² d1,8,15 |
| (Japan II) | GEM | 42 | 21 | 66 | 3.7 | 7.7 | 11.9 | 11 | GP: Gemcitabine: 1000mg/m² d1, 8+Cisplatin: 25mg/m² d1, 8 |
| Malka et al., (14) | C-GEMOX | 76 | 43 | 61 | 6.1 | 11 | 23 | 61 | GEMOX: Gemcitabine: 1000 mg/m² d1+Oxaliplatin 100 mg/m² d1 |
| (France II) | GEMOX | 74 | 42 | 62 | 5.5 | 12.4 | 23 | 57 | Cetuximab 500 mg/m² d1 or d2 |
| Lee et al., (15) | GEMOX+erlotinib | 135 | 91 | 59 | 5.8 | 9.5 | 30 | 3 | GEMOX: Gemcitabine: 1000 mg/m² d1+Oxaliplatin 100 mg/m² d2 |
| (South Korea III) | GEMOX | 133 | 79 | 61 | 4.2 | 9.5 | 16 | 5 | Erlotinib 100 mg qd |
| Philip et al., (16) | FP+radiotherapy | 18 | 7 | 69 | 5.8 | 13.5 | 0 | CHRT: radiotherapy: 50 Gy in 25 fractions, 5 days a week+5 FU, 300 mg/m²+Cisplatin 20 mg/m² d1-4 and d29-32 (Cisplatin 80 mg/m² at day 1 or 2 and day 29 or 30) | |
| (France II) | GEMOX | 16 | 8 | 75 | 11 | 19.9 | 4 | GEMOX: Gemcitabine: 1000 mg/m² d1+Oxaliplatin: 100 mg/m² d1, q2w | |
| Moehler et al., (17) | GEM+sorafenib | 49 | 29 | 64 | 3 | 8.4 | 14 | 33 | Gemcitabine 1000 mg/m² |
| (Germany II) | GEM | 48 | 25 | 65 | 4.9 | 11.2 | 10 | 35 | Sorafenib: 400mg, bid, po |
| Chen et al., (18) | C-GEMOX | 62 | 28 | 61 | 6.7 | 10.6 | 27 | 11 | GEMOX: Gemcitabine: 800 mg/m², d1+Oxaliplatin: 85mg/m², d1 |
| (Taiwan II) | GEMOX | 60 | 30 | 59 | 4.1 | 9.8 | 15 | 2 | Cetuximab: 500mg/m², d1 |
| Novarino et al., (19) | Folfox 4 | 22 | 11 | 62 | 5.4 | 14.1 | 13.6 | 6 | Folfox4: Oxaliplatin: 85mg/m² d1+LV 200mg/m² d1, 2+5-FU: 400/600mg/m²/d1-2 |
| (Italy) | GEM | 18 | 12 | 65 | 3.9 | 8.3 | 0 | 5 | Gemcitabine: 1250 mg/m² |
| Sasaki et al., (20) | GS | 30 | 16 | 68 | 5.6 | 8.9 | 20 | 10 | GS: Gemcitabine: 1000 mg/m², d1, 15+S1 80‐120mg/m², bid po d1-14 q4w |
| (Japan II) | GEM | 32 | 20 | 75 | 4.3 | 9.2 | 9.4 | 7 | GEM: Gemcitabine: 1000 mg/m², d1, 8, 15 q4w |
| Morizane et al., (21) | GS | 51 | 27 | 66 | 7.1 | 12.5 | 36.4 | 31 | GS: Gemcitabine: 1000 mg/m², d1, 8+S1: 60‐100mg/m², bid po d1-14 |
| (Japan II) | S1 | 50 | 28 | 63 | 4.2 | 9 | 17.4 | 2 | S1: 80-120mg/m², po bid for 4 weeks, followed by a 2-week rest |
| Morizane et al., (21) | GP | 49 | 31 | 59 | 5.7 | 10.1 | 9 | 24 | GP: Gemcitabine: 1000mg/m² d1, 8+Cisplatin: 60mg/m² d1 |
| (Korea II) | SP | 47 | 31 | 60 | 5.4 | 9.9 | 10 | 14 | SP: S1 80‐120mg/m2, bid po d1-14+Cisplatin: 60mg/m² d1 |
| Sakai et al., (22) | GPS | 7.4 | 13.5 | 41.5 | GPS: Gemcitabine: 1000mg/m² d1+Cisplatin: 25 mg/m²+S1: 80mg/m² d1-7 | ||||
| (Japan III) | GP | 5.5 | 12.6 | 15 | GC: Gemcitabine 1000 mg/m² d1, 8+Cisplatin 25 mg/m² d1, 8 | ||||
| Markussen et al., (23) | XELOX+GEM | 47 | 23 | 65 | 5.7 | 8.7 | 17 | 1 | XELOX+GEM: Oxaliplatin: 50 mg/m²+Gemcitabine: 1000 mg/m²+Capecitabine: 650 mg/m², bid, d1-14 |
| (Denmark II) | GP | 49 | 23 | 65 | 7.3 | 12 | 16 | 21 | GP: Cisplatin: 25 mg/m², d1, 8+Gemcitabine: 1000mg/m² d1, 8 |
| Kim et al., (24) | GEMOX | 54 | 35 | 62 | 3 | 8 | 10 | GEMOX: Gemcitabine: 1000 mg/m²+Oxaliplatin: 100mg/m² | |
| (Korea III) | GEMOX+erlotinib | 49 | 33 | 59 | 6.1 | 10.2 | 20 | Erlotinib: 100 mg qd po | |
| Valle et al., (25) | RAM+GP | 106 | 6.47 | 10.45 | 31.1 | 52 | Merestinib: 80 mg po qd | ||
| (II) | MER+GP | 102 | 6.97 | 14.03 | 19.6 | 48 | Ramucirumab: 8 mg/kg d1, 8 | ||
| GP | 101 | 6.64 | 13.04 | 32.7 | 33 | GP: Gemcitabine: 1000 mg/m² + Cisplatin: 25 mg/m² d1, 8 | |||
| Ramaswamy et al., (26) | GP | 141 | 53 | 52 | 8.02 | 44 | 12 | GP: Gemcitabine: 1000mg /m² d1, 8+Cisplatin: 25mg/m² d1, 8 | |
| (India) | GEMOX | 154 | 53 | 52 | 7.79 | 56 | 4 | GEMOX: Gemcitabine: 1000mg /m² d1+Oxaliplatin: 100mg/m² d1 |